Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

RECAP 2 i Psilocybins adfærdsmæssige effekter

3. november 2026 opdateret af: University of Wisconsin, Madison

Erfaringsrolle, bevidst bevidsthed og plasticitet i Psilocybins adfærdsmæssige effekter - opfølgningsundersøgelse (Recap 2-undersøgelsen)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.

Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.

Participants will:

  • Receive one of four possible combinations of medications
  • Undergo an MRI
  • Complete questionnaires
  • Undergo transcranial magnetic stimulation (TMS) and EEG
  • Volunteer for an open-label follow-up phase of study

Studieoversigt

Detaljeret beskrivelse

The purpose of this study is to investigate the role that inducing neuroplasticity plays in the behavioral effects of psilocybin in people with modest decrements in emotional wellbeing.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • UW School of Medicine and Public Health

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
  • Physically healthy; does not meet criteria for an exclusionary medical condition
  • English-speaking (able to provide consent and complete questionnaires)
  • Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
  • Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)

Exclusion Criteria:

  • Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
  • Exclusionary medical conditions
  • Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
  • Clinically significant electrocardiogram (ECG)
  • Use of psychotropic or CNS-altering medications within 3 months of screening
  • Hypertension or tachycardia

Participants invited to participate in the 28-day open label follow-up phase will:

  1. Fully complete all activities associated with the randomized phase, including the virtual Day 84 assessment, before being approached about participation in the open label phase.

  2. Participants who meet stopping criteria during the randomized phase are not eligible to enroll in the open label phase.

  3. Participants who withdraw from the randomized phase are not eligible to enroll in the open label phase.

  4. Enrollment into the open label phase must occur in the following sequence:

    1. participants who have fully completed the randomized phase are screened for eligibility;
    2. eligible participants meet with the study team and provide informed consent for the open label phase;
    3. baseline eligibility is reassessed to confirm that participation in the open label phase remains appropriate and safe.

The Principal Investigator may decline or defer open-label enrollment when unresolved concerns make participation unsafe or scientifically inappropriate.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group 1: Psilocybin and intravenous (IV) midazolam

Psilocybin (25 mg) + IV midazolam

25mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

1mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

Eksperimentel: Group 2: Psilocybin and IV saline

Psilocybin (25 mg) + IV saline (placebo for midazolam)

25mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

1mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

Saline will be administered as a placebo for midazolam

Eksperimentel: Group 3: Psilocybin and IV midazolam

Psilocybin (1 mg/control) + IV midazolam

25mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

1mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

Eksperimentel: Group 4: Psilocybin and IV saline

Psilocybin (1 mg/control) + IV saline

25mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

1mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

Saline will be administered as a placebo for midazolam

Eksperimentel: Exploratory Open Label Follow-Up Phase

Psilocybin (25 mg)

25mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

1mg of psilocybin

Andre navne:
  • Psilocybin
  • Psilocibin

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
Tidsramme: Baseline to 7 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 7 days post-dose
Change in Brief Experiential Avoidance Questionnaire (BEAQ)
Tidsramme: Baseline to 7 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 7 days post-dose
Change in Probabilistic Reversal Learning (PRL)
Tidsramme: Baseline to 7 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 7 days post-dose
Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
Tidsramme: Baseline to 7 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 7 days post-dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in WEMWBS
Tidsramme: Baseline to 28 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 28 days post-dose
Change in BEAQ
Tidsramme: Baseline to 28 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 28 days post-dose
Change in PRL
Tidsramme: Baseline to 28 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 28 days post-dose
Change in TEP amplitude
Tidsramme: Baseline to 28 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 28 days post-dose
Altered States of Consciousness (ASC) questionnaire
Tidsramme: Dosing 1 day

Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience. During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience.

Dosing 1 day
Emotional Breakthrough Inventory (EBI)
Tidsramme: Dosing 1 day

The EBI is a 6-item scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience. Participants rate to what extent the statements apply to their experience by marking a single line across each scale. Scale ranges from not at all to very much so. Higher scores (more slashes toward the 'very much so' end) on the scale have been associated with enhanced well-being following psychedelic use

Dosing 1 day
Psychological Insight Questionnaire (PIQ)
Tidsramme: Dosing 1 day

The PIQ is a 23-item instrument designed to query self-perceived attainment of insight during a psychedelic medicine session. Items are rated on a 6-point Likert scale, 0 = no not at all and 5 = extremely. Possible scares range from 0-115, with higher scores indicating greater insight.

Dosing 1 day

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Charles Raison, MD, University of Wisconsin, Madison

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. august 2025

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

14. november 2024

Først indsendt, der opfyldte QC-kriterier

15. november 2024

Først opslået (Faktiske)

18. november 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2024-0852
  • A538900 (Anden identifikator: UW- Madison)
  • SMPH/PSYCHIATRY/PSYCHIATRY (Anden identifikator: UW- Madison)
  • Protocol Version 9/30/2026 (Anden identifikator: UW- Madison)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner